Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosimilar to Xolair (omalizumab)
Shots:
- Kashiv will receive an upfront and is eligible to receive subsequent milestones and royalties, following the successful development and approval of AVT23 which is currently in clinical development
- Alvotech will get an exclusive license to commercialize AVT23 (developed and manufactured by Kashiv). The agreement was valid in all 27 countries of the EU, the UK, Australia, Canada, and New Zealand
- Omalizumab, a humanized mAb targeting free IgE. Xolair which contains omalizumab & is indicated for diseases i.e., sev. persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic spontaneous urticaria. The therapy was developed by Novartis and licensed by Roche
Ref: Globenewswire | Image: Alvotech
Related News:- Alvotech Entered into Commercialization Agreement with Advanz Pharma for AVT23, a Proposed Biosimilar to Xolair (omalizumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
